Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
2.850
-0.130 (-4.36%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
The company is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Sergio Traversa |
Contact Details
Address: 2222 Ponce de Leon Boulevard, Floor 3 Coral Gables, Florida 33134 United States | |
| Phone | 786-629-1376 |
| Website | relmada.com |
Stock Details
| Ticker Symbol | RLMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553643 |
| CUSIP Number | 75955J402 |
| ISIN Number | US75955J4022 |
| Employer ID | 45-5401931 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | Chief Executive Officer and Director |
| Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer |
| Charles S. Ence CPA, M.B.A. | Chief Accounting and Compliance Officer |
| Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer |
| Gina DiGuglielmo | Vice President and Head of Clinical Operations |
| Dr. Marco Pappagallo M.D. | Chief Clinical Officer |
| John Hixon | Head of Commercial |
| Dr. Andrew Cutler | Senior Clinical Development Advisor |
| Dr. Richard M. Mangano | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Sep 12, 2024 | EFFECT | Notice of Effectiveness |
| Sep 6, 2024 | UPLOAD | Filing |
| Aug 30, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| May 30, 2024 | 8-K | Current Report |
| May 8, 2024 | 10-Q | Quarterly Report |
| Apr 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2024 | DEF 14A | Other definitive proxy statements |